Novartis (NOVN SW) Q3 2026 (USD): Net Sales 14.5bln (exp. 14.5bln), Adj. Operating Income 6.04bln (exp. 5.51bln),Core EPS 2.46 (Exp. 2.28)

• Entresto Sales 1.17bln
• Cosentyx Sales 1.86bln

• Raises FY26 operating income to be in line to grow low single-digit (prev. guided decline low single-digit)
• Net sales to grow low single-digit.

A clean profit beat on in-line revenue, with the FY operating income guidance swung from a guided decline to low single-digit growth, is the combination that has historically produced the stronger and more durable reaction in large-cap pharma: the market treats guidance direction as more informative than the quarter itself. The composition matters here, since revenue met consensus while adjusted operating income beat materially, pointing to margin and cost performance rather than top-line surprise; peers reporting in this pattern have tended to see the move consolidate rather than extend unless the guidance raises broader sector read-across. Entresto and Cosentyx remain the franchise barometers for this name, and their prints relative to the loss-of-exclusivity narrative around key products is what separates one-off beats from re-ratings. Read-across to the wider European pharma complex and the SMI is the usual follow-on, with the FX translation effect on USD-reported figures a recurring complication when interpreting the raise. The items worth watching are the call commentary on the drivers behind the margin beat and whether analysts treat the guidance revision as conservative, since management in this position has typically under-pitched initial upgrades.